Study: Rare mutations in PALB2, CHEK2, and ATM: how much do they increase cancer risk?
Contents
At a glance | Questions for your doctor |
Findings | In-depth |
Clinical trials | Limitations |
Guidelines | Resources |
STUDY AT A GLANCE
This study is about:
The breast, ovarian, and cancer risks associated with rare mutations in , , and .
Why is this study important?
Some mutations in , , and are rare, making it difficult to determine the exact increased cancer risk for people who carry them. Patients with these mutations need to know this information so that they and their healthcare providers can make appropriate decisions about their cancer screenings and treatment.
Study findings:
- mutations: There were three rare mutations studied.
- Two were associated with an increased risk of breast cancer, and one was not.
- None of the three rare mutations studied were associated with increased or ovarian cancer risk.
- mutations:
- One rare mutation was associated with an increased risk of breast cancer, but not with or ovarian cancer.
- mutations: There were six rare mutations studied.
- Four were associated with increased breast cancer risk, although the risk was not as high as those found in some of the and mutations.
- One mutation was not associated with increased breast cancer risk for European women, but was associated with increased cancer risk for European men.
- One mutation that was only found in African men and women was associated with both increased breast cancer and cancer risk.
- None of the six mutations were associated with an increased risk for ovarian cancer.
What does this mean for me?
It is important to remember that this study looked at just a handful of rare mutations in , and , and cannot be used to draw conclusions about all mutations in these genes. However, this work indicates that it is important to know the exact mutation a patient has, as well as his/her personal and family history of cancer when developing a plan for cancer screening or assessing potential treatment options. More work needs to be done to confirm some of these findings, and to determine other rare mutations that may increase a patient’s cancer risk or not have an effect on a patient’s cancer risk. Patients should work with their healthcare providers to understand their genetic test results and determine what screenings and treatments are best for them.
Posted 9/27/16
Share your thoughts on this XRAYS article by taking our brief survey.
References
Southey MC, Goldgar DE, Winqvist R, et al. “, and rare variants and cancer risk: data from COGS.” Journal of Medical Genetics. 2016; 0: 1-12. http://jmg.bmj.com/content/early/2016/09/02/jmedgenet-2016-103839.short?rss=1
This article is relevant for:
People who tested positive for one of the rare variants in CHEK2, ATM or PALB2 that are covered in this study
This article is also relevant for:
people with a genetic mutation linked to cancer risk
previvors
Be part of XRAY:
IN DEPTH REVIEW OF RESEARCH
Study background:
Many multi-gene panel tests look for mutations in , , and . However, while mutations in these genes are rare, some versions of the mutations are even less common. Our current understanding of cancer risk associated with mutations in , , and results from studying the most common mutations in these genes. From this past work, researchers realized that in some cases, mutations in could increase cancer risk as much as a mutation in a gene, while mutations in and increase cancer risk to a lesser extent but above the level of an average person.
Studying rare mutations is difficult because the study has to be large enough to see how mutations in these genes affect cancer risk. Yet researchers have a hard time finding enough people with these rare mutations to study cancer risk and draw conclusions that can be used to make cancer risk management decisions.
Melissa Southey and her colleagues from The University of Melbourne and other institutions around the world published work in the Journal of Medical Genetics in June 2016 that assessed the cancer risk associated with a handful of specific, very rare mutations in , , and .
Researchers of this study wanted to know:
What are the breast, ovarian, and cancer risks associated with rare mutations in , , and ?
Population(s) looked at in the study:
The participants in this study were from studies participating in three consortiums:
- The Breast Cancer Association Consortium (BCAC)
- The majority of women in the studies from this consortium were of European ancestry (42,671 cases and 42,164 controls), compared to Asians (5,795 cases and 6,624 controls), and African Americans (1,046 cases and 932 controls). All of the women had invasive breast cancer.
- The Cancer Association Group to Investigate Cancer Alterations in the Genome (PRACTICAL)
- The majority of men in the studies from this consortium were of European ancestry (22,301 cases and 22,320 controls), compared to African American men (623 cases and 569 controls).
- The Ovarian Cancer Association Consortium (OCAC)
- The majority of women in the studies from this consortium were of European ancestry (16,287 cases and 14,542 controls), compared to Asian women (720 cases and 93 controls), and African American women (150 cases and 36 controls).
These consortiums are all part of the Collaborative Oncological Gene-environment Study (COGS) with a total of 176,873 participants.
Study findings:
- mutations: There were three rare mutations studied.
- Two mutations were associated with increased breast cancer risk ( c.1592delT and c.3113G>A), while one was not ( c.2816T>G). In all, 41 people were found to have the c.1592delT mutation, 52 people had the c.3113G>A mutation, and 295 people had the c.2816T>G mutation.
- None of the three rare mutations studied showed an association with increased or ovarian cancer risk.
- mutations:
- The one rare mutation ( c.7271T>G) studied was found to be associated with an increased risk of breast cancer, but not for or ovarian cancer; only 13 people in this study had this mutation.
- mutations: There were six rare mutations studied.
- Four mutations ( c.349A>G, c.538C>T, c.715G>A, c.1036C>T) were associated with increased breast cancer risk, although the risk was not as high as the and mutations studied. The study showed that 62 people had the c.349A>G mutation, 300 people had the c.538C>T mutation, 24 people had the c.715G>A, and 11 people had the c.1036C>T mutation.
- One mutation ( c1312G>T) was not associated with increased breast cancer risk for European women, but was associated with increased cancer risk for European men; 34 people in this study had this mutation.
- One mutation ( c.1343T>G) was only found in African men and women, and was associated with increased breast cancer and cancer risk; 46 people in this study had this mutation.
- None of the six mutations were associated with an increased risk for ovarian cancer.
Limitations:
The cancer risks calculated in this study apply to very few people because, of the hundreds of mutations that can occur in , , and , the study looked at only 10 specific mutations. Because these are rare mutations, the sample size for some of them was too small, even from an international collaboration, to yield a definitive conclusion (especially as seen in the mutations that were carried by less than 20 people). Additionally, the international approach does not greatly improve the risk estimates for the mutations that are only found in certain populations (such as the mutation that was only found in African American patients). This means that the cancer risks calculated in this study might not apply to the few people who have one of these rare mutations. Finally, it is always important to remember mutation status is not the only measure of increased cancer risk. Even if a person has a mutation that was found to not increase cancer risk in this study, there are other factors that are involved in determining cancer risk including family history and lifestyle factors
Conclusions:
The results of this study suggest that some of the rare mutations in and may be associated with increased risk of breast cancer, putting these women at “high risk.” This indicates that these women should have more screening and should discuss risk-reducing measures with their health care providers. However, more work needs to be done, especially in developing more methods that can be used to estimate these risks accurately for these rare mutations that are difficult to study with human populations. This study is a clear example of how much work and how many research participants are needed to get reliable estimates of cancer risks associated with specific mutations.
It is important to note that this study looked at a handful of specific mutations in , , or ATM; it did not look at the risk of having any mutation in these genes. People with mutations in , , or should consult with a genetics expert who can look at both their gene mutation as well as their personal and family history of cancer to help them estimate their cancer risk.
Posted 9/27/16
Share your thoughts on this XRAYS article by taking our brief survey.
The National Comprehensive Cancer Network (NCCN) provides guidelines for management of breast cancer risk in people with inherited mutations linked to breast cancer. We recommend that you speak with a genetics expert who can look at your personal and family history of cancer and help you determine the best risk management plan.
or
- Beginning at age 40 (or earlier based on your family history of breast cancer)
- recommend yearly
- Beginning at age 30-35
- consider yearly with and without contrast
, or
- Beginning at age 40 (or earlier based on family history):
- recommend yearly
- consider yearly breast with and without contrast
- No specific breast cancer screening guidelines. Risk management should be based on your family history of cancer.
- Beginning at age 30 (or earlier based on family history):
- recommend yearly
- consider yearly breast with contrast
- discuss risk-reducing mastectomy
- Beginning at age 30 (or earlier based on family history):
- recommend yearly
- recommend yearly breast with and without contrast
- discuss risk-reducing mastectomy with your doctor
- Beginning at age 18, learn to be aware of changes in breasts.
- Beginning at age 25:
- clinical breast exam every 6-12 months beginning at age 25 or 10 years earlier than the youngest age of onset in the family
- Beginning at age 30:
- yearly and breast with contrast beginning at age 30 or earlier based on the youngest breast cancer in the family
- discuss risk-reducing mastectomy with your doctor
- After age 75
- discuss benefits and limitations of continued screening with your doctor
- Beginning at age 30:
- clinical breast examination by a health care provider every 6 months starting at age 30
- recommend yearly
- recommend yearly with and without contrast
- discuss risk-reducing mastectomy with your doctor
- Beginning at age 18, learn to be aware of changes in your breasts.
- Beginning at age 20:
- clinical breast examination by a healthcare provider every 6 months
- recommend yearly breast with and without contrast beginning at age 20 or at the age of earliest breast cancer diagnosis if there is a history of breast cancer before age 20 in family
- Beginning at age 30
- recommend yearly
- Consider risk reducing mastectomy.
- After age 75
- discuss benefits and limitations of continued screening with your doctor
Updated: 12/17/2023
- I was diagnosed with breast cancer before age of 45; should I consider genetic testing?
- I tested negative for mutations in and , despite being diagnosed with breast cancer before the age of 45; should I consider additional genetic testing?
- Members of my family have a mutation in , , or ATM; should I consider genetic testing?
- I tested positive for a mutation in a gene for which cancer risk is not well understood; how can I be sure I get new information on my cancer risk as more research is completed?
- Can you refer me to a genetics expert?
The following are risk-management studies enrolling people with inherited mutations. Check study listings or contact the study team to see if you are eligible.
Multiple cancers
- NCT02665195: Registry Of MultiPlex Testing (PROMPT). The goal of this online research PROMPT registry of people who have had genetic panel testing is to follow people with mutations or variants in genes on these panels, so that patients, physicians and researchers can more clearly understand these lesser-known risks. This study is open to people with an or in sseveral different genes including , , , , , , and others.
- The Risk Factor Analysis of Hereditary Breast and Ovarian Cancer In Women with , or Mutations This study seeks to improve researchers’ understanding of how hormonal, reproductive and lifestyle factors may be associated with cancer in this high-risk population.
cancer
- NCT03805919: Men at High Genetic Risk for Cancer. This study uses in high-risk men. This study is open to men with mutations in , , , , , , , , , and other genes.
- NCT05129605: Cancer Genetic Risk Evaluation and Screening Study (PROGRESS). This study looks at the effectiveness of MRI works as a screening tool for men at high risk for cancer. This study is open to men with inherited mutations in , , , , , , , , , , , , , , , and other genes.
Ovarian cancer
- Validating a Blood Test for Early Ovarian Cancer Detection in High-risk Women and Families: MicroRNA Detection Study (MiDE). The goal of this effort is to develop a test to detect ovarian cancer. This study is enrolling people with mutations in , , , , , , and other genes.
- NCT05287451: Risk Reducing With Delayed as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention. This study looks at the outcomes of women with inherited mutations in , , , and who remove their then remove their ovaries compared to women who undergo standard-of-care removal of their ovaries and at the same time.
Pancreatic cancer
- NCT03250078: A Pancreatic Cancer Screening Study in Hereditary High Risk Individuals. The main goal of this study is to screen and detect pancreatic cancer and precursor lesions in individuals with a strong family history or genetic predisposition to pancreatic cancer. and Magnetic cholangiopancreatography (MRI/MRCP) will be utilized to screen for early- pancreatic lesions.
- NCT02206360: Pancreatic Cancer Early Detection Program. This pancreatic cancer screening study uses esophageal to screen for pancreatic cancer in high-risk people. The study is open to people who have or an in , , , CDKN2A, or .
- NCT03568630: Blood Markers of Early Pancreas Cancer. This pancreatic cancer study involves blood samples taken over time to lidentify biomarkers of pancreatic cancer in high-risk people. The study is open to people with a mutation linked to increased cancer risk.
- NCT02478892: Preliminary Evaluation of Screening for Pancreatic Cancer in Patients with an Inherited Genetic Risk Due to a , , or Mutation. This study uses and endoscopic to screen for pancreatic cancer in people with a BRCA1/2, or mutation.
Additional risk-management clinical trials for people with inherited mutations may be found here.
Updated: 09/11/2022
FORCE offers many peer support programs for people with inherited mutations.
- Our Message Boards allow people to connect with others who share their situation. Once registered, you can post on the Diagnosed With Cancer board to connect with other people who have been diagnosed.
- Our Peer Navigation Program will match you with a volunteer who shares your mutation and situation.
- Our moderated, private Facebook group allows you to connect with other community members 24/7.
- Check out our virtual and in-person support meeting calendar.
- Join one of our Zoom community group meetings.
Updated: 08/06/2022
The following resources can help you locate a genetics expert near you or via telehealth.
Finding genetics experts
- The National Society of Genetic Counselors website has a search tool for finding a genetic counselor by specialty and location or via telehealth.
- InformedDNA is a network of board-certified genetic counselors providing this service by telephone. They can also help you find a qualified expert in your area for face-to-face genetic counseling if that is your preference.
- Gene-Screen is a third-party genetic counseling group that can help educate, support and order testing for patients and their families.
- JScreen is a national program from Emory University that provides low-cost at-home genetic counseling and testing with financial assistance available.
- Grey Genetics provides access to genetic counselors who offer genetic counseling by telephone.
- The Genetic Support Foundation offers genetic counseling with board-certified genetic counselors.
Related experts
Genetics clinics
- The American College of Medical Genetics website has a tool to find genetics clinics by location and specialty.
Other ways to find experts
- Register for the FORCE Message Boards and post on the Find a Specialist board to connect with other people who share your situation.
- The National Cancer Institute (NCI)-designated comprehensive cancer centers have genetic counselors who specialize in cancer.
- FORCE's toll-free helpline (866-288-RISK, ext. 704) will connect you with a volunteer board-certified genetic counselor who can help you find a genetics expert near you.
Updated: 07/21/2023
Who covered this study?
Breast Cancer News
Rare genetic mutations tied to higher risk of breast cancer This article rates 3.5 out of 5 stars
News.com.au
Also published in:
The same article was also covered by Nine.com.au
Rare genes increase breast cancer risk This article rates 2.5 out of 5 stars
Medical Xpress
World-first study confirms rare genetic mutations cause high breast cancer risk This article rates 2.5 out of 5 stars